Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivothym phase II immunotherapy study in previously treated thymic carcinoma and type B3 thymoma
NL-OMON60403Phase 2Active, not recruiting
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab and ipilimumab in thymic carcinoma (TC) and thymoma (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Progression Free Survival Rate at 6 months. Started Aug 2024; status: active, not recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
thymic carcinoma (TC)thymoma
Beyond the preview
Go deeper on NL-OMON60403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60403.